All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
DOTA, with a full name of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, is an organic compound. Its not a cancer cell surface molecule biomarker, but usually used as a complexing agent, especially for lanthanide ions. Its complexes have medical applications as contrast agents and cancer treatments.DOTA can be conjugated to monoclonal antibodies by attachment of one of the four carboxyl groups as an amide. The remaining three carboxylate anions are available for binding to the yttrium ion. The modified antibody accumulates in the tumour cells, concentrating the effects of the radioactivity of 90Y.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-LC059 | Anti-DOTA h(41BB-CD3ζ) CAR, pCDCAR1 | Mouse | scFv-41BB-CD3ζ | Lentiviral | T cell | ||||
CAR-ZP2750 | Anti-DOTA (XR183) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | XR183 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP2751 | Anti-DOTA (XR183) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | XR183 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
XS-1022-ZP179 | Anti-DOTA (LG1) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | LG1 | Mouse | scFv-41BB-CD32ζ | Lentiviral vector | T cell | ||
XS-1022-ZP180 | Anti-DOTA (LG1) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | LG1 | Mouse | scFv-CD28-CD32ζ | Lentiviral vector | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION